Snake venom zinc metalloproteinase that catalyzes the conversion of prothrombin (F2) to alpha-thrombin through formation of a thrombin intermediate, without requiring additional cofactors. Also inhibits collagen-dependent platelet aggregation in vitro, an effect that does not depend on proteolytic activity. In vivo, at low doses, induces defibrin(ogen)ation when injected intravenously or intramuscularly into mice. At higher doses, causes sudden death by intravenous administration due to numerous occluding thrombi in pulmonary vessels. Binds 1 zinc ion per subunit. Clotting activity on human plasma is not abrogated by the plasma proteinase inhibitors alpha(2) macroglobulin and murinoglobulin. Monomer. Expressed by the venom gland. Glycosylated. The N-terminus is blocked. Does not degrade components of the extracellular matrix. Does not induce local tissue alterations, such as hemorrhage, myonecrosis, and edema, in mice. Does not induce systemic hemorrhage, thrombocytopenia nor prolongation of the bleeding time following intravenous administration. Belongs to the venom metalloproteinase (M12B) family. P-III subfamily. P-IIIa sub-subfamily.